e-drug
[Top] [All Lists]

[e-drug] Sign-on letter: Support Colombia compulsory license request for lopinavir/ritonavir (Kaletra)

E-DRUG: Support Colombia compulsory license request for lopinavir/ritonavir 
(Kaletra)
-----------------------------------------------------------------------------------------

Dear Colleagues,

On July 16, Colombian NGOs filed requests for an open compulsory  
license on AIDS drug lopinavir/ritonavir  with the Colombian  
government.  An open license would permit generic competition with  
Abbott's patented product Kaletra.  Generic lopinavir/ritonavir is  
available in many countries at prices significantly less than half  
what Abbott charges Colombia's public health sector (and five times  
less what Abbott charges Colombia's private sector).  An open  
license would save patients and health programs money and facilitate  
access to an important AIDS medicine.

The health NGOs' compulsory license request comes more than three  
months after the same groups requested an open license directly from  
Abbott Laboratories.  To date, Abbott has not responded to the  
groups' request.

More information is available here:
<http://www.essentialaction.org/access/index.php?/archives/166- 
Colombia-Health-Organizations-file-for-compulsory-license-on- 
lopinavirritonavir.html>

Essential Action is collecting signatures in support of the license  
request.  If you would like to sign on, please send your  
organization's name (or your name and organizational affiliation, if  
any, if you would like to sign on as an individual), your mailing  
address and email address to  
<peter.maybarduk@essentialinformation.org>.  The deadline for sign- 
ons is Tuesday, August 5, 2008.

Thank you,
Peter Maybarduk
Essential Action
peter.maybarduk@essentialinformation.org
Skype: petesystem
------

Doctor
ALVARO URIBE VELEZ
PRESIDENTE DE LA REPUBLICA DE COLOMBIA
E.   S.   D.

Doctor
GUSTAVO VALBUENA QUIÑONES
SUPERINTENDENTE DE INDUSTRIA Y COMERCIO
E.  S.  D.

cc:
Doctor
DIEGO PALACIO BETANCOURT
MINISTRO DE LA PROTECCION SOCIAL
E. S. D.


We are organizations from around the world concerned about providing  
treatment to people with HIV/AIDS, ensuring all people have access to  
needed medicines, and promoting public health. We write in support of  
the July 16, 2008 Colombian civil society request for issuance of a  
compulsory license on the medicine lopinavir/ritonavir (Kaletra),(1)  
[FN1: The request was filed by the HIV/AIDS Working Group (Mesa de  
Organizaciones con trabajo en VIH/SIDA), RECOLVIH Colombian Network  
of Persons Living with HIV/AIDS (Red Colombiana de personas viviendo  
con el VIH), Foundation IFARMA-Health Action Internacional, and  
Mission Health (Fundación Misión Salud)]

Under the World Trade Organization's Agreement on Trade-Related  
Aspects of Intellectual Property (TRIPS) and Andean Community  
Decision 486, Colombia is free to issue compulsory licenses to  
advance public interest objectives. The WTO's Doha Declaration on the  
TRIPS Agreement and Public Health "affirm[s] that the [TRIPS]  
Agreement can and should be interpreted and implemented in a manner  
supportive of WTO members' right to protect public health and, in  
particular, to promote access to medicines for all."

Issuing a compulsory license in this case will help promote access to  
medicines for all. Lopinavir/ritonavir is a key medicine in the  
treatment of HIV/AIDS. The high price charged by Abbott, the patent  
holder for this medicine, constitutes a barrier to access and hinders  
efforts to make antiretroviral treatment available in Colombia to all  
who need it.

A compulsory license for lopinavir/ritonavir in Colombia would allow  
the state to obtain and offer imported generics, as well as permit  
the local production of lopinavir/ritonavir.  The result could be  
greater product availability for patients, robust competition, and  
savings for the state, which could be directed to other public needs.

Thank you for this opportunity to comment.  We urge that you give all  
due consideration to this license request.


<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] Sign-on letter: Support Colombia compulsory license request for lopinavir/ritonavir (Kaletra), Peter Maybarduk <=